Communication Is Key In Adapting Production To Pandemic Component Supply Disruptions
Executive Summary
US FDA is looking at risk-based approach for reporting changes in out-of-stock components such as plastic bioreactor bags, filters and tubing sets that are in short supply.
You may also be interested in...
Pharma Supply Chain Disruptions Increased Another 74% in 2021, Resilinc Says
The COVID-19 pandemic has both caused problems such as reduced preventive maintenance and exacerbated other issues, such as slowing recovery from extreme weather events, according to Resilinc CEO.
BARDA Expands US Domestic Production Of Single-Use Systems For Vaccine Manufacturing
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.
Pandemic Response Strains Global Biopharmaceutical Reactor Capacity
Distress grows as manufacturers wait for suppliers to boost production. One idea: stretch inventories by qualifying single-use bioreactors for reuse.